Диссертация (1139884), страница 19
Текст из файла (страница 19)
JAm Coll Cardiol 2003;42:185–197.93.Paquette M, Roy D, Talajic M, Newman D, Couturier A, Yang C, Dorian P.Role of gender and personality on quality-of-life impairment in intermittentatrial fibrillation. Am J Cardiol 2000;86:764–768.94.Pedersen SS, Denollet J, de Jonge P, Simsek C, Serruys PW, van DomburgRT. Brief depression screening with the PHQ-2 associated with prognosisfollowing percutaneous coronary intervention with paclitaxel-elutingstenting. J Gen Intern Med. 2009 Sep;24(9):1037-42.95.Pereira AP, Cesarino CB, Martins MR, Pinto MH, Netinho JG.
Associationsamong socio-demographic and clinical factors and the quality of life ofostomized patients. Rev Lat Am Enfermagem. 2012 Jan-Feb;20(1):93-100.96.Plumb VJ, Windecker S, Epstein AE et al. Nonpharmacologic Therapy ofAtrial Fibrillation and Atrial Flutter. Am J Geriatr Cardiol 1998;7:21–6.97.Prins MH, Marrel A, Carita P, et al. Multinational development of aquestionnaire assessing patient satisfaction with anticoagulant treatment: the‘Perception of Anticoagulant Treatment Questionnaire’ (PACT-Q). HealthQual Life Outcomes.
2009;7:9.98.Reynolds MR, Ellis E, Zimetbaum P. Quality of Life in Atrial Fibrillation:MeasurementToolsandImpactofInterventions.JCardiovascElectrophysiol. 2008 July ; 19(7): 762–768.99.Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence ofage, sex, and atrial fibrillation recurrence on quality of life outcomes in apopulation of patients with new-onset atrial fibrillation: The FibrillationRegistry Assessing Costs, Therapies, Adverse events and Lifestyle(FRACTAL) study. Am Heart J 2006;152:1097–1103.100.Rienstra M, Van Veldhuisen DJ, Hagens VE, Ranchor AV, VeegerNJGM, Crijns HJGM, Van Gelder IC. Gender-related differences in rhythmcontrol treatment in persistent atrial fibrillation. Data of the Rate Control119versus Electrical Cardioversion (RACE) study.
J Am Coll Cardiol2005;46:1298–1306.101.Rollman BL, Herbeck Belnap B, Mazumdar S, Houck PR, He F,Alvarez RJ, Schulberg HC, Reynolds CF 3rd, McNamara DM. A positive 2item Patient Health Questionnaire depression screen among hospitalizedheart failure patients is associated with elevated 12-month mortality. J CardFail. 2012 Mar;18(3):238-45.102.Saliba W, Wazni OM. Sinus rhythm restoration and treatment success:insight from recent clinical trials.
Clin Cardiol. 2011 Jan;34(1):12-22.103.Schumacher M, Olschewski M, Schulgen G. Assessment of quality oflife in clinical trials.Stat Med. 1991;10:1915-1930.104.SearchQuotes.Hippocrates.Availableat:http:/www.searchquotes.com/quotation/Cure_sometimes,_treat_often,_comfort_always./118801/. Accessed September 1, 2011.105.Singh SN, Tang XC, Singh BN, Dorian P, Reda DJ, Harris CL,Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD, Lopez B,Raisch DW, Ezekowitz MD.
Quality of life and exercise performance inpatients in sinus rhythm versus persistent atrial fibrillation. J Am CollCardiol 2006;48:721–730.106.SoRelle R. Direct myocardial revascularization a “placebo effect,”according to study chief. Circulation 2000;102:E9036–9037.107.Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, ReynoldsMR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development andvalidation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT)Questionnaireinpatientswithatrialfibrillation.CircArrhythmElectrophysiol.
2011 Feb;4(1):15-25. Epub 2010 Dec 15.108.Spertus JA, Tooley J, Jones P, et al. Expanding the outcomes inclinical trials of heart failure: The quality of life and economic componentsof the EPHESUS (EPlerenone’s neuroHormonal Efficacy and SurvivalStudy). Am Heart J 2002;143:636–642.120109.Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence,incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study.Heart 2001;86:516–521.110.Sud S, Massel D, Klein GJ, Leong-Sit P, Yee R, Skanes AC, Gula LJ,Krahn AD.
The expectation effect and cardiac pacing for refractoryvasovagal syncope. Am J Med 2007;120:54–62.111.ten Doesschate MC, Koeter MW, Bockting CL, Schene AH; DELTAStudy Group. Health related quality of life in recurrent depression: acomparison with a general population sample. J Affect Disord. 2010Jan;120(1-3):126-32.112.Testa MA, Simonson DC. Assesment of quality-of-life outcomes. NEngl J Med 1996;334:835–840.113.The EuroQol Group.
Euro-Qol: A new facility for measurement ofhealth-related quality of life. Health Policy 1990;16:199–208114.Thrall G, Lane D, Carroll DLGYH. Quality of life in patients withatrial fibrillation: A systematic review. Am J Med 2006;119:448.e441–448.e419.115.Thrall G, Lip GYH, Carrol D et al. Depression, Anxiety, and Qualityof life in patients with Artrial Fibrillation.Chest 2007;132:1259-1264.116.Tondo C, Mantica M, Russo G, Avella A, De LL, Pappalardo A,Fagundes RL, Picchio E, Laurenzi F, Piazza V, Bisceglia I.
Pulmonary veinvestibule ablation for the control of atrial fibrillation in patients withimpaired left ventricular function. Pacing Clin Electrophysiol 2006;29:962–970.117.Van den Berg MP, Hassink RJ, Tuinenburg AE et al. Quality of life inpatients with paroxysmal atrial fibrillation and its predictors: importance ofthe autonomic nervous system. Eur Heart J 2001;22:247–53.118.Ware JEJ.
SF-36 Health Survey: Manual and Interpretation Guide.Boston: The Health Institute, New England Medical Center; 1993.121119.Ware JJr, Kosinski M, Keller SD. A 12-Item Short-Form HealthSurvey: Construction of scales and preliminary tests of reliability andvalidity. Med Care 1996;34:220–233.120.Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M,Saliba W, Bash D, Schweikert R, Brachmann J, Gunther J, Gutleben K,Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis S, Rossillo A,Bonso A, Natale A. Radiofrequency ablation vs antiarrhythmic drugs asfirst-line treatment of symptomatic atrial fibrillation: A randomized trial.JAMA 2005;293:2634–2640.121.Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, WhalleyD, Kanagaratnam L, Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M.The Australian Intervention Randomized Control of Rate in AtrialFibrillation Trial (AIRCRAFT).
J Am Coll Cardiol 2003;41:1697–1702.122.Weerasooriya R, Jais P, Hocini M, Scavee C, MacLe L, Hsu LF,Sandars P, Garrigue S, Clementy J, Haissaguerre M. Effect of catheterablation on quality of life of patients with paroxysmal atrial fibrillation.Heart Rhythm 2005;2:619–623.123.Weisberg RB, Beard C, Pagano ME, Maki KM, Culpepper L, KellerMB. Impairment and functioning in a sample of primary care patients withgeneralized anxiety disorder: results from the primary care anxiety project.Prim Care Companion J Clin Psychiatry. 2010;12(5).122Приложение 1Опросник врачуДанная анкета предназначена для того, чтобы узнать мнение врачей –кардиологов о тактике лечения у конкретных пациентов с фибрилляциейпредсердий.
Ответьте, пожалуйста, на все предложенные вопросы, указав вкаждом пункте один или несколько показателей, сыгравших роль в выборетактики лечения (восстановление синусового ритма).Анамнез□ молодой возраст□ небольшая частота развития пароксизмов (менее 4 в год)□ небольшая давность аритмии (менее 1 года)□ короткая длительность пароксизма (менее 48 часов)□ эффективность предшествующей антиаритмической терапии□ впервые возникшая ФП□ желание пациентадругое_____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________Данные объективного осмотра__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________Данные инструментальных исследований□ отсутствие дилатации ЛП (объём менее 90 мл, размер менее 4,5 см)другое_____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________123Данная анкета предназначена для того, чтобы узнать мнение врачей –кардиологов о тактике лечения у конкретных пациентов с фибрилляциейпредсердий.
Ответьте, пожалуйста, на все предложенные вопросы, указав вкаждом пункте один или несколько показателей, сыгравших роль в выборетактики лечения (ритм-урежающая терапия).Анамнез□ пожилой возраст□ частые пароксизмы (более 4 в год)□ большая давность аритмии (более 1 года)□ неэффективность кардиоверсии□ субъективно хорошая переносимость ФП□ противопоказания к применению препаратов для поддержания синусовогоритмадругое_____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________Данные объективного осмотра__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________Данные инструментальных исследований□ дилатация ЛП (объём более 90 мл, размер более 4,5 см)другое_____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________124Приложение 2Канадская шкала тяжести ФП (Саnadian Cardivascular Society Severity inArtrial Fibrillation, CCS-SAF)ФИО________________________________________________________Шаг 1 – СимптомыУкажите наличие следующих симптомов:А.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
